Hepatitis B virus (HBV) infection still remains a major public health issue in the Asia–Pacific
region. Most of the burden of HBV-related disease results from infections acquired in infancy …

Antiviral drugs (AvDs) are the primary resource in the global battle against viruses, including
the recent fight against corona virus disease 2019 (COVID-19). Most AvDs require multiple …

Background Entecavir and tenofovir–disoproxil–fumarate are first-line nucleos (t) ide
analogs (NA) for treatment of hepatitis B virus (HBV) infections; however, their long-term …

Background and Aims Real‐world data for treatment effectiveness and renal outcomes in
chronic hepatitis B (CHB) patients who were switched to the new and safer prodrug tenofovir …

For long-term treatment of hepatitis B virus (HBV) infection, switching from tenofovir-
disoproxil-fumarate (TDF) to tenofovir-alafenamide (TAF) may prevent renal dysfunction and …

Background Tenofovir alafenamide fumarate has been used in late pregnancy; however, no
data exist regarding its safety and effectiveness in early and middle pregnancy for mothers …

Background and aims Antiviral agents for chronic hepatitis B (CHB) reduced the risk of
hepatocellular carcinoma (HCC) development. The outcomes of entecavir (ETV), tenofovir …

Background and Aims Hepatitis B virus (HBV) infection continues to threaten millions of lives
across the globe, despite universal vaccination efforts. Current guidelines for screening …

Abstract Background Traditional Chinese Medicine (TCM), has been used for hepatocellular
carcinoma (HCC) at every therapeutic stage, even before tumor formation. However, the …

With the improved efficacy and accessibility of antiviral agents as well as the concerns about
disease progression, there is a hot discussion on whether HBeAg-negative chronic hepatitis …